Retatrutide Research Peptide Multiple Specifications Spot Supply Quick Delivery
7582 Inquiries
2381089-83-2
Pharmaceutical Grade
99%
shenzhen
ZHONGMA
100mg per vial; 10vials/box
Yes
2027-09-30
GLP-1,Retatrutide,Tirzepatide,Peptides
-
Product Details
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceRetatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide inhibits human GCGR, GIPR and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively and mouse GCGR, GIPR, and GLP-1R with EC50 values of 2.32, 0.191 and 0.794 nM, respectively. It is an important tool for obesity research.Retatrutide potently activates the GLP-1R signaling pathway to stimulate glucose-dependent insulin secretion through activity at the GIP receptor (GIPR) or the GLP-1R.Retatrutide is a synthetic peptide with glucose-lowering effects. It is an antidiabetic agent against type 2 diabetes (T2D), stimulating insulin and suppressing glucagon secretion in a glucose-dependent manner.Retatrutide was also shown to delay gastric emptying, lower fasting and postprandial glucose concentration, decrease food intake and reduce body weight in patients with type 2 diabetes.
Retatrutide (LY-3437943) was discovered by the American pharmaceutical company Eli Lilly and Company. It is a triple glucagon hormone receptor agonist (GLP-1, GIP, and GCGR receptors) for obesity. The 2024 Lasker~DeBakey Clinical Medical Research Award has been given to Joel Habener and Svetlana Mojsov for their discovery of a new hormone GLP-1(7-37) and to Lotte Knudsen for her role in developing sustained acting versions of this hormone as a treatment for obesity.Basic Info-
Product Name:
Retatrutide
Other Name:Retatrutide;GIPR/GLP-1R;LY3437943Retatrutide;Retalutide;Retatrutide (sodium salt);Retatrutide RT5;retatrutide 5mg;Retatratide
CAS No.:2381089-83-2
InChIKeys:MLOLQJNKXBNWFW-SAGGEDDASA-N
Molecular Weight:0
EC Number:200-001-8
Color/Form:White lyophilized
Categories:
Characteristics-
Water Solubility:
Soluble in water (5mg/ml).
Storage Conditions:-20°C
Critical Temperature & Pressure:-20°C
Research-
Class:
Triple agonist — GCGR, GIPR, GLP-1R
Status:Investigational (Phase 3)
Mechanism:Simultaneously activates glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Engineered from the native GIP backbone with amino acid substitutions to confer GCGR and GLP-1R activity.
EC50 (Human GCGR):5.79 nM
EC50 (Mouse GIPR):0.191 nM
EC50 (Mouse GLP1R):0.794 nM
EC50 (Mouse GCGR):2.32 nM
EC50 (Human GLP1R):0.775 nM
EC50 (Human GIPR):0.0643 nM
Source:Jastreboff AM, et al. N Engl J Med. 2023;389(6):514-526.DOI
Clinical Development:
References-
ChEMBL:DrugBank:KEGG DRUG:PubChem:Literature:
NEJM: Jastreboff et al. (2023) — Phase 2 Trial ; FDA Drugs@FDA
Disclaimer:Retatrutide is an investigational compound not yet approved by FDA or EMA. This listing is for industrial and laboratory research use only. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
GLP-1,Retatrutide,Tirzepatide,Peptides
-
Location:
Room A008, 704#, Building 11, Shiliu Street Block, Liangzhu Subdistrict, Yuhang District, Hangzhou City, Zhejiang Province
-
Payment Terms:
TT against copy of documents,100% TT in advance
-
Average lead Time:
1 days
-
Total Annual Revenue:
$1 million-$2.5 million
-
Total Employees:
11-50
-
Year of Establishment:
2025
-
-
Inquiry History7582 Inquiries
Country Product Purchase Quantity Date Posted
United States
Retatrutide
1 MT Nov 7, 2026
Germany
Retatrutide
2 MT Nov 7, 2026
Norway
Retatrutide
100 PCS Nov 7, 2026
United States
Retatrutide
4 MT Nov 6, 2026
Israel
Retatrutide
10 MT Nov 6, 2026
Australia
Retatrutide
10 MG Nov 6, 2026
United Kingdom
Retatrutide
100 Nov 6, 2026
United States
Retatrutide
30 MG Nov 6, 2026
United States
retatrutide
1 G Nov 6, 2026
Canada
retatrutide
20 MG Nov 6, 2026
South Africa
Retatrutide
10 G Nov 6, 2026
United States
Retatrutide
1 KG Nov 6, 2026
Australia
Retatrutide
25 MT Nov 6, 2026
United States
Retatrutide
20 Nov 6, 2026
United States
Retatrutide
20 MT Nov 6, 2026
Australia
Retatrutide
10 MG Nov 5, 2026
Australia
Retatrutide
100 PCS Nov 5, 2026
Slovakia
retatrutide
20 MG Nov 5, 2026
France
retatrutide
10 MG Nov 5, 2026
United States
retatrutide
150 MG Nov 5, 2026 Post an enquiry for this product
More from this Seller
-
-
-
Survodutide BI 456906 Research Peptide Raw Powder 99% Purity Factory Supply
Pharmaceutical Grade / 99%
$279/UNIT FOB
-
-
-
-
AHK-Cu Copper Tripeptide-3 Powder 99% High Purity Cosmetic Peptide Raw Material for Scalp Care 100MG
Pharmaceutical Grade / 99%
$71/UNIT FOB
-
-
-
-
Humanin 99% High peptide content white powder GLP/GLP-1 10mg customization
Pharmaceutical Grade / 99%
$304/UNIT FOB
-
-
-
-
High Quality Wholesale Price Peptides Factory Direct Supply IGF-1LR3 Powder CAS 946870-92-4 1g /raw material 1mg
Pharmaceutical Grade / 99%
$178/UNIT FOB
-
-
-
-
High-Purity Semaglutide 99% Raw Powder for Research Use, CAS 910463-68-2
Pharmaceutical Grade / 99%
$69/UNIT FOB
-
-
-
-
Reduced Glutathione GSH Peptide Lyophilized Powder, Research Grade Quality, In Stock with Custom Vial Packing Available
Pharmaceutical Grade / 99%
$75/UNIT FOB
-